The Priority Review

Clinical trials Brief

Hoffmann-La Roche registers Phase III enicepatide trial

The study plans to enroll 8200 participants and is expected to start on January 6, 2027. It aims to evaluate the efficacy and safety of enicepatide, a dual GLP-1/GIP receptor agonist, in reducing major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.

Primary source

ClinicalTrials.gov registry record, November 5, 2026

A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease

Read the source: A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease clinicaltrials.gov

Machine-summarized from the source above; not independently reported. How we use automation